secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apogee Therapeutics, Inc. (APGE)
CIK:        0001974640
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0000950170-25-106228
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apogee reports positive APG777 Phase 2 data and Q2 net loss of $66.1M
---------------------------------------------------------------------

- APG777 APEX Part A met primary endpoint: 71.0% EASI reduction vs 33.8% placebo (p<0.001).
- Cash, cash equivalents and marketable securities at $621.2M as of June 30, 2025; runway into Q1 2028.
- Net loss of $66.1M for Q2 2025, up from $33.8M in Q2 2024, driven by higher R&D expenses.
- Phase 2 Part B readout accelerated to mid-2026; Phase 3 plans on track for 2026.
- First patient dosed in Phase 1b combination trial of APG279 vs DUPIXENT in atopic dermatitis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1974640/000095017025106228/0000950170-25-106228-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1974640/000095017025106228/apge-20250811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-106228

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer